PL2433953T3 - Peptydy o zdolności przenikania przez błonę komórkową - Google Patents

Peptydy o zdolności przenikania przez błonę komórkową

Info

Publication number
PL2433953T3
PL2433953T3 PL10777770T PL10777770T PL2433953T3 PL 2433953 T3 PL2433953 T3 PL 2433953T3 PL 10777770 T PL10777770 T PL 10777770T PL 10777770 T PL10777770 T PL 10777770T PL 2433953 T3 PL2433953 T3 PL 2433953T3
Authority
PL
Poland
Prior art keywords
cell membrane
permeable peptides
peptides
permeable
membrane
Prior art date
Application number
PL10777770T
Other languages
English (en)
Inventor
Mariko Morishita
Kozo Takayama
Reiji Nishio
Nobuo Ida
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2433953T3 publication Critical patent/PL2433953T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
PL10777770T 2009-05-20 2010-05-19 Peptydy o zdolności przenikania przez błonę komórkową PL2433953T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009122096 2009-05-20
JP2010071774 2010-03-26
PCT/JP2010/058420 WO2010134537A1 (ja) 2009-05-20 2010-05-19 細胞膜透過性ペプチド
EP10777770.8A EP2433953B1 (en) 2009-05-20 2010-05-19 Cell membrane-permeable peptides

Publications (1)

Publication Number Publication Date
PL2433953T3 true PL2433953T3 (pl) 2015-12-31

Family

ID=43126214

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10777770T PL2433953T3 (pl) 2009-05-20 2010-05-19 Peptydy o zdolności przenikania przez błonę komórkową

Country Status (13)

Country Link
US (1) US8772449B2 (pl)
EP (1) EP2433953B1 (pl)
JP (1) JP5653214B2 (pl)
KR (1) KR101783291B1 (pl)
CN (1) CN102428096B (pl)
AU (1) AU2010250452B2 (pl)
BR (1) BRPI1008230B1 (pl)
CA (1) CA2762551C (pl)
ES (1) ES2546304T3 (pl)
MX (1) MX2011011960A (pl)
PL (1) PL2433953T3 (pl)
RU (1) RU2548807C2 (pl)
WO (1) WO2010134537A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法
KR20150014483A (ko) 2012-05-11 2015-02-06 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US9730984B2 (en) 2012-05-11 2017-08-15 Gemvax & Kael Co., Ltd. Composition for preventing or treating rheumatoid arthritis
KR101799904B1 (ko) 2012-07-11 2017-11-22 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
JP6510410B2 (ja) 2012-09-19 2019-05-08 ジェムバックス アンド カエル カンパニー，リミティド 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
ES2758451T3 (es) 2012-09-19 2020-05-05 Gemvax & Kael Co Ltd Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado
JP6474786B2 (ja) 2013-04-19 2019-02-27 ジェムバックス アンド カエル カンパニー，リミティド 虚血性損傷の治療及び予防用の組成物
EP3004883B1 (en) 2013-06-07 2022-09-14 Gemvax & Kael Co., Ltd. Gv1001, gemcitabine and capecitabine for use in the treatment of pancreatic cancer in high eotaxin baseline level patients
TWI539960B (zh) 2013-06-21 2016-07-01 凱爾傑姆維克斯有限公司 激素分泌調節劑、包括其的組成物以及其用途
CN103555729B (zh) * 2013-10-14 2016-08-24 成都华创生物技术有限公司 一种改造的trail基因序列、表达方法及应用
WO2015060673A1 (ko) 2013-10-23 2015-04-30 주식회사 카엘젬백스 전립선 비대증 치료 및 예방용 조성물
KR102494803B1 (ko) 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
JP6367950B2 (ja) 2013-12-17 2018-08-01 ジェムバックス アンド カエル カンパニー，リミティド 前立腺癌治療用組成物
EP3130345B9 (en) 2014-04-11 2022-05-04 Gemvax & Kael Co., Ltd. Peptide having fibrosis inhibitory activity and composition containing same
WO2015167067A1 (ko) 2014-04-30 2015-11-05 주식회사 카엘젬백스 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3929296A1 (en) 2015-01-30 2021-12-29 The Regents of The University of California Protein delivery in primary hematopoietic cells
CN107405380B (zh) 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
RU2712623C2 (ru) 2015-03-31 2020-01-30 Илдонг Фарм. Ко., Лтд. Фармацевтическая композиция для предотвращения и лечения заболеваний глаз, содержащая в качестве активного ингредиента белок слияния, в котором слиты проникающий в ткань пептид и препарат против фактора роста эндотелия сосудов
WO2016190660A1 (ko) 2015-05-26 2016-12-01 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
KR101647804B1 (ko) * 2015-06-24 2016-08-11 한국과학기술연구원 신규 세포투과 펩타이드 및 이의 용도
WO2017003267A1 (ko) 2015-07-02 2017-01-05 주식회사 젬백스앤카엘 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2017127567A1 (en) * 2016-01-19 2017-07-27 Genebiologics, Llc Production of arginine-rich proteins and use as a fertilizer and germination enhancer
JP7114481B2 (ja) 2016-04-07 2022-08-08 ジェムバックス アンド カエル カンパニー，リミティド テロメラーゼ活性の増加及びテロメアの延長の効能を有するペプチド、及びこれを含む組成物
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
EP3556766A4 (en) * 2016-12-16 2020-07-22 Avixgen Inc. CYTOPLASMATIC TRANSDUCTION PEPTIDE AND INTRACELLULAR MESSENGER WITH IT
JP2019099578A (ja) * 2017-12-06 2019-06-24 参天製薬株式会社 細胞膜透過性ペプチドを含有する眼科用医薬組成物
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
PE20212132A1 (es) 2018-04-03 2021-11-05 Ngm Biopharmaceuticals Inc Agentes de union a c3 y metodos para su uso
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN109553659B (zh) * 2018-11-26 2022-06-21 上海华新生物高技术有限公司 一种细胞穿透肽及透皮干扰素
CN109575107B (zh) * 2018-11-26 2022-03-08 上海华新生物高技术有限公司 一种细胞穿透肽及可表达口服干扰素的双歧杆菌
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20240041983A1 (en) 2020-09-07 2024-02-08 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
US20230383037A1 (en) 2020-10-16 2023-11-30 Josho Gakuen Educational Foundation Composition
CN114805593A (zh) * 2021-01-19 2022-07-29 盛世泰研(广东)健康科技有限公司 一种具有穿膜功能的Penetratin-hSOD1及其制备方法与应用
KR20220157778A (ko) * 2021-05-21 2022-11-29 원큐어젠 주식회사 세포 투과성 펩타이드 및 글루카곤 유사 펩타이드-1 수용체 작용제를 포함하는 복합체
WO2023166179A1 (en) 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2702285B2 (ja) 1992-08-21 1998-01-21 バイオジェン，インコーポレイテッド Ｔａｔ由来の輸送ポリペプチド
JP3770666B2 (ja) 1996-09-20 2006-04-26 株式会社ティ・ティ・エス技術研究所 経粘膜吸収製剤用組成物
JP2002530059A (ja) * 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
US7291594B2 (en) 2002-10-11 2007-11-06 Sanwa Kagaku Kenkyusho Co., Ltd. GLP-1 derivative and preparation thereof absorbable via mucous membrane
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
JP2005185271A (ja) * 2003-12-03 2005-07-14 Credia Japan:Kk 膜透過性ペプチド核酸
AU2005304973A1 (en) * 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
WO2009107766A1 (ja) * 2008-02-28 2009-09-03 東レ株式会社 経鼻投与用医薬組成物
CN102580061B (zh) * 2011-12-01 2015-04-22 武汉健宇生物医药科技有限公司 一种鼻用型胰岛素制剂及制备方法

Also Published As

Publication number Publication date
CA2762551C (en) 2016-11-22
RU2548807C2 (ru) 2015-04-20
EP2433953A1 (en) 2012-03-28
CA2762551A1 (en) 2010-11-25
BRPI1008230B1 (pt) 2019-05-28
EP2433953B1 (en) 2015-07-08
KR20120064650A (ko) 2012-06-19
AU2010250452B2 (en) 2014-06-05
JPWO2010134537A1 (ja) 2012-11-12
KR101783291B1 (ko) 2017-09-29
ES2546304T3 (es) 2015-09-22
CN102428096B (zh) 2015-03-25
MX2011011960A (es) 2011-12-06
BRPI1008230A2 (pt) 2016-03-08
JP5653214B2 (ja) 2015-01-14
RU2011151877A (ru) 2013-06-27
US8772449B2 (en) 2014-07-08
US20120065124A1 (en) 2012-03-15
EP2433953A4 (en) 2013-06-05
CN102428096A (zh) 2012-04-25
AU2010250452A1 (en) 2011-11-10
WO2010134537A1 (ja) 2010-11-25

Similar Documents

Publication Publication Date Title
PL2433953T3 (pl) Peptydy o zdolności przenikania przez błonę komórkową
HK1249547A1 (zh) 鹽藻糖基化欠缺細胞
GB0908613D0 (en) T Cell Reseptors
ZA201109522B (en) T cell receptors
GB201017019D0 (en) Cell selection
EP2475029A4 (en) BATTERY
EP2445045A4 (en) FUEL CELL
EP2478584A4 (en) BATTERY
EP2448051A4 (en) FUEL CELL
GB201017421D0 (en) Cell
EP2413405A4 (en) FUEL CELL
EP2441107A4 (en) THIN BATTERY
EP2432059A4 (en) FUEL CELL
EP2416430A4 (en) FUEL CELL
GB0920775D0 (en) Cells
ZA201108446B (en) FViII-DERIVED PEPTIDES
EP2467892A4 (en) FUEL CELL
ZA201203722B (en) Peptide
EP2416429A4 (en) FUEL CELL
GB0917143D0 (en) Cell stack
EP2439209A4 (en) PEPTIDES BASED ON ENDOKININS C / D
EP2463946A4 (en) FUEL CELL
GB0920035D0 (en) Cell
TWI372482B (en) Battery
GB0911790D0 (en) Peptides